DIMP is the lead antiandrogen of the
phthalimide group of nonsteroidal AR
ligands, and a variety of AR ligands with higher
affinity for the AR have been derived from DIMP and thalidomide.[10][11]
^
abHashimoto Y, Tanatani A, Nagasawa K, Miyachi H (2004). "Thalidomide as a multitarget drug and its application as a template for drug design". Drugs of the Future. 29 (4): 383.
doi:
10.1358/dof.2004.029.04.792298.
ISSN0377-8282.
^
abLiu B, Su L, Geng J, Liu J, Zhao G (October 2010). "Developments in nonsteroidal antiandrogens targeting the androgen receptor". ChemMedChem. 5 (10): 1651–1661.
doi:
10.1002/cmdc.201000259.
PMID20853390.
S2CID23228778.
^
abHashimoto Y (July 2003). "Structural development of synthetic retinoids and thalidomide-related molecules". Cancer Chemotherapy and Pharmacology. 52 (Suppl 1): S16–S23.
doi:
10.1007/s00280-003-0590-3.
PMID12819930.
S2CID22663471.
^
abcdBoris A, Scott JW, DeMartino L, Cox DC (March 1973). "Endocrine profile of a nonsteroidal antiandrogen N-(3,5-dimethyl-4-isoxazolylmethyl)phthalimide (DIMP)". Acta Endocrinologica. 72 (3): 604–614.
doi:
10.1530/acta.0.0720604.
PMID4739363.
^Ahlin K, Forsberg JG, Jacobsohn D, Thore-Berger B (1975). "The male genital tract and the nipples of male and female offspring of rats given the non-steroidal antiandrogens DIMP and Sch 13521, during pregnancy". Archives d'Anatomie Microscopique et de Morphologie Expérimentale. 64 (1): 27–44.
PMID1217898.
^Heyns W, Verhoeven G, De Moor P (May 1976). "Androgen binding in rat uterus cytosol. Study of the specificity". Journal of Steroid Biochemistry. 7 (5): 335–343.
doi:
10.1016/0022-4731(76)90092-3.
PMID180344.
^Kaur P, Khatik GL (2016). "Advancements in Non-steroidal Antiandrogens as Potential Therapeutic Agents for the Treatment of Prostate Cancer". Mini Reviews in Medicinal Chemistry. 16 (7): 531–546.
doi:
10.2174/1389557516666160118112448.
PMID26776222.